The expression levels of HE4, TSGF, and CD105-MVD in different clinical stages of cervical cancer need to be further explored to provide new ideas for targeted drug therapy of moderate to advanced cervical cancer. The gene discussed is WFDC2; the disease is cervical carcinoma.